CIA
BMY.RT

Choate Investment Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Choate Investment Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,079
Closed -$6K – 313
2020
Q4 		$6K Sell
9,079
-4,140
-31% -$8.82K ﹤0.01% 280
2020
Q3 		$29K Sell
13,219
-3,681
-22% -$10.5K ﹤0.01% 264
2020
Q2 		$61K Sell
16,900
-1,314
-7% -$4.74K ﹤0.01% 241
2020
Q1 		$69K Sell
18,214
-470
-3% -$1.55K 0.01% 232
2019
Q4 		$56K Buy
+18,684
New +$48.6K ﹤0.01% 227

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Choate Investment Advisors's BMY.RT Position: Q1 2021 in Review

Choate Investment Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 9,079 shares — an estimated $6K sold.

Choate Investment Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $69K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Choate Investment Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Choate Investment Advisors sold 9,079 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $6K.
  • Choate Investment Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Choate Investment Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $69K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Choate Investment Advisors's 13F filing for Q1 2021, filed 7 May 2021.